# Dogwood Therapeutics Inc. (DWTX)

Source: https://www.quantisnow.com/company/DWTX
Generated: 2026-11-17T16:25:12.693Z

- Ticker: DWTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- SEC CIK: 0001818844

## Latest DWTX news and filings

- 2026-11-16 17:07 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-dogwood-therapeutics-inc-6793427)
- 2026-11-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-dogwood-therapeutics-inc-6779902)
- 2026-11-06 14:18 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-dogwood-therapeutics-inc-6778274)
- 2026-11-05 13:45 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6775073)
- 2026-11-05 13:30 UTC [Earnings] [Dogwood Therapeutics Announces Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-third-quarter-2026-financial-results-6774993)
- 2026-10-30 20:02 UTC [SEC Form S-3] [SEC Form S-3 filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-dogwood-therapeutics-inc-6765154)
- 2026-10-27 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-dogwood-therapeutics-inc-6759220)
- 2026-10-19 12:30 UTC [Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.](https://www.quantisnow.com/insight/dogwood-announces-5-million-private-placement-with-ck-life-sciences-6750183)
- 2026-10-19 12:45 UTC [SEC Form 8-K] [SEC Form 8-K filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-dogwood-therapeutics-inc-6749947)
- 2026-10-06 12:45 UTC [Conference Announcement] [Dogwood to Participate in the 2026 Maxim Growth Summit](https://www.quantisnow.com/insight/dogwood-to-participate-in-the-2026-maxim-growth-summit-6738396)
- 2026-09-14 12:45 UTC [Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial](https://www.quantisnow.com/insight/dogwood-announces-completion-of-enrollment-in-ongoing-halneuron-phase-2b-6713893)
- 2026-08-17 12:30 UTC [Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026](https://www.quantisnow.com/insight/dogwood-to-host-virtual-kol-event-to-discuss-halneuron-for-6684421)
- 2026-08-14 15:14 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-dogwood-therapeutics-inc-6682417)
- 2026-08-14 14:10 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-dogwood-therapeutics-inc-6682229)
- 2026-08-13 12:50 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6679579)
- 2026-08-13 12:30 UTC [Leadership Update] [Dogwood Therapeutics Announces Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-second-quarter-2026-financial-results-6679516)
- 2026-07-20 12:30 UTC [Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026](https://www.quantisnow.com/insight/dogwood-enrolls-first-200-patients-in-ongoing-halneuron-phase-2b-6642010)
- 2026-06-30 12:45 UTC [Leadership Update] [Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board](https://www.quantisnow.com/insight/dogwood-therapeutics-appoints-iain-dukes-venture-partner-at-orbimed-as-6620203)
- 2026-06-17 20:55 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-amendments-to-articles-6607115)
- 2026-06-17 17:19 UTC [SEC Form 4] [SEC Form 4 filed by Director De La Rosa Abel](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-de-la-rosa-abel-6606327)
- 2026-06-17 17:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Thomas John C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-thomas-john-c-6606326)
- 2026-06-17 17:17 UTC [SEC Form 4] [SEC Form 4 filed by Director Whitley Richard James](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-whitley-richard-james-6606325)
- 2026-06-17 17:16 UTC [SEC Form 4] [SEC Form 4 filed by Director Keefer David R](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-keefer-david-r-6606324)
- 2026-05-18 12:45 UTC [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-commencement-of-halneuron-chemotherapy-induced-neuropathic-pain-6559378)
- 2026-05-15 15:13 UTC [SEC Form SCHEDULE 13G filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-dogwood-therapeutics-inc-6556406)
- 2026-05-15 13:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-dogwood-therapeutics-inc-6556141)
- 2026-05-14 12:50 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6552736)
- 2026-05-14 12:30 UTC [Dividends] [Dogwood Therapeutics Announces First Quarter 2026 Financial Results](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-first-quarter-2026-financial-results-6552624)
- 2026-05-07 12:30 UTC [Earnings Date] [Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026](https://www.quantisnow.com/insight/dogwood-therapeutics-to-report-first-quarter-2026-financial-results-on-6537775)
- 2026-04-27 18:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-dogwood-therapeutics-inc-6516103)
- 2026-04-23 13:00 UTC [Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-6511935)
- 2026-04-17 21:26 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-dogwood-therapeutics-inc-6505395)
- 2026-04-15 13:00 UTC [Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy](https://www.quantisnow.com/insight/dogwood-therapeutics-announces-fda-acceptance-of-sp16-investigational-new-drug-6500708)
- 2026-03-26 13:00 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6470278)
- 2026-03-18 20:30 UTC [SEC Form 10-K] [SEC Form 10-K filed by Dogwood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-dogwood-therapeutics-inc-6458294)
- 2026-03-18 13:00 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6455713)
- 2026-03-18 12:30 UTC [Dividends] [Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://www.quantisnow.com/insight/dogwood-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-6455416)
- 2026-03-12 20:30 UTC [SEC Form 8-K] [Dogwood Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/dogwood-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6444908)
- 2026-03-06 21:20 UTC [SEC Form 4] [SEC Form 4 filed by SVP OF OPERATIONS Grosswald Ralph](https://www.quantisnow.com/insight/sec-form-4-filed-by-svp-of-operations-grosswald-ralph-6435018)
- 2026-03-06 21:18 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Walsh Angela](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-walsh-angela-6435007)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/DWTX
- Earnings history: https://www.quantisnow.com/earnings/DWTX
- Dividend history: https://www.quantisnow.com/dividends/DWTX
- Insider transactions: https://www.quantisnow.com/insiders/DWTX
- Options chain: https://www.quantisnow.com/options/DWTX
- SEC 8-K filings only: https://www.quantisnow.com/company/DWTX/8-k
- RSS and alerts for DWTX: https://www.quantisnow.com/docs/rss-feeds.md
